Drug Profile
Research programme: RNA therapeutics - Arcturus Therapeutics/Viridos
Alternative Names: LUNAR-RPLLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Arcturus Therapeutics; Synthetic Genomics
- Developer Arcturus Therapeutics; Viridos
- Class RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Unspecified in USA
- 27 Sep 2021 Synthetic Genomics is now called Viridos
- 01 Mar 2021 Arcturus Therapeutics has multiple patents and patent pending applications for its LNA, UNA oligomer and mRNA therapeutics in multiple countries